Objectives: The increasing prevalence of resistant bacteria such as fluoroquinolone-resistant or extended-spectrum b-lactamase-producing strains in pathogens causing acute uncomplicated cystitis has been of concern in Japan. Faropenem sodium is a penem antimicrobial that demonstrates a wide antimicrobial spectrum against both aerobic and anaerobic bacteria. It is stable against a number of b-lactamases.
Introduction
Acute uncomplicated cystitis (cystitis) is a common disease in women. The most common cystitis pathogen is Escherichia coli; however, in Japan the increase in antimicrobial-resistant bacteria, such as fluoroquinolone-resistant and extendedspectrum b-lactamase (ESBL)-producing bacteria, has raised concern. In a recent report, between 10% and 30% of E. coli strains isolated from cystitis and complicated cystitis patients were fluoroquinolone resistant. 1 In another Japanese study of complicated urinary tract infections (UTIs), 29% and 5% of E. coli strains were fluoroquinolone resistant or ESBL producing, respectively. 2 In China, the rates of fluoroquinolone-resistant and ESBL-producing strains in UTIs were surprisingly higher, at 65% and 30%, respectively. 3 These resistant strains can be spread worldwide by selection or plasmid-mediated transmission. 4, 5 Therefore, other regimens for cystitis treatment, especially in Eastern Asia, are required.
Faropenem sodium is a b-lactam antimicrobial with a hybrid structure combining features of penicillins and cephalosporins # The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2014; 69: 1675 -1680 doi:10.1093/jac/dku014 Advance Access publication 6 February 2014 that was originally synthesized by Suntory Co., Ltd (currently Asubio Pharma Co., Ltd, Kobe, Japan) in 1985 as the first and only oral penem antimicrobial. 6, 7 Faropenem has a wide antimicrobial spectrum against aerobic Gram-positive, aerobic Gram-negative and anaerobic bacteria. It is mainly excreted by the kidney. Faropenem is extremely stable against a number of b-lactamases in vitro and it has good clinical and antimicrobial efficacies against respiratory tract infections, UTIs and skin infections, which are approved indications in Japan. 8 -12 Therefore, we speculated that faropenem could be a potential antimicrobial for the treatment of cystitis, for which ESBL-producing strains are increasing as causative bacteria. The aim of this study was to evaluate the efficacy of faropenem against cystitis and to determine the optimal faropenem treatment duration.
Methods

Participants
We included women aged ≥20 years, with any cystitis symptoms, such as micturition pain, urinary frequency, urge to urinate, or lower abdominal pain with pyuria and bacteriuria. Pyuria was defined by the following: for uncentrifuged urine, .10 white blood cells (WBCs)/mm 3 as counted by a designated device or counting chamber or a positive leucocyte esterase result using urine test paper. For centrifuged urine, .5 WBCs/high power field in the urinary sediment were required. Bacteriuria was defined as . 10 3 cfu/mL of live bacteria in urine obtained by a catheter or . 10 4 cfu/mL in a midstream urine catch. The target bacteria were Staphylococcus spp., Enterococcus faecalis, Streptococcus agalactiae and Enterobacteriaceae. If bacteria other than the above were isolated, a committee determined whether the patient would be enrolled in the study. The exclusion criteria included the following: a previous episode of b-lactam hypersensitivity; current pregnancy or breast feeding; cardiac, hepatic or renal failure; treatment with other antimicrobials within the previous 10 days; and infection with bacteria that were not expected to be susceptible to faropenem. Patients who were judged as ineligible for the study by the study investigators were also excluded.
Study design
The study was a multicentre, randomized, comparative, open-label, controlled study using a central registration system for enrolment of participants from 35 institutions throughout Japan. The test drug was a 200 mg faropenem sodium tablet that was administered three times daily (600 mg/day) for 3 or 7 days. We assumed a 90% efficacy rate for both treatment groups and the non-inferiority margin was 10% (a error 0.05, b error 0.1). Because 77 participants per group were required for data analysis, 150 participants per group were targeted, taking uncompleted terminations, dropouts and missing data into account. The eligible participants were randomly assigned to 3 or 7 day treatment groups at the central registration centre (Clinical Research Collaboration Network: CREC Net, Kitakyushu, Japan). Randomization of patients was performed using a random number list. The registration centre faxed the study arm allocation to the medical facility for each patient who was recruited.
Microbiological and clinical efficacies were evaluated 5 -9 days or 4 -6 weeks after the completion of faropenem treatment.
Endpoints
The endpoints of this study were based on the latest Japanese guidelines for urogenital infections. 13 The primary endpoint was microbiological outcome 5-9 days after treatment completion. 'Eradication' was defined as , 10 3 cfu/mL urine after treatment. 'Failure' was sub-classified as 'persistence' and 'replaced'. The microbiological outcome 4 -6 weeks after treatment completion demonstrated cystitis recurrence. 'Failure' was sub-classified as 'relapsed' and 'reinfection'. The second endpoint was clinical outcome 5 -9 days or 4 -6 weeks after treatment. 'Cure' and 'failure' were defined as the absence and presence of symptoms, respectively.
'Safety' included adverse events, harmful clinical symptoms and abnormal changes in laboratory results.
Antimicrobial susceptibilities
Urine samples were collected at the first patient visit after enrolment, 5 -9 days after treatment completion and 4-6 weeks after treatment completion. All samples were assessed using Uricult-E w (Orion Diagnostica, Espoo, Finland). Dipped Uricults were immediately sent to the central laboratory (Kyurin Corporation, Kitakyushu, Japan).
Dipped Uricults were incubated for 24 h and the bacterial counts and strains were identified. The isolates were tested for susceptibility to faropenem, cefcapene, fosfomycin calcium and levofloxacin using the broth microdilution method. The isolated E. coli strains for which cefcapene MICs were .2 mg/L were screened for ESBLs by PCR and the type of ESBL was determined by sequencing according to the method reported by Muratani et al.
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Statistical analysis
Discrete data, including microbiological and clinical efficacies, were expressed as percentages and frequencies and analysed by Fisher's exact test. Continuous data, including age and other subject background data, were analysed by Student's t-test, and the results are presented as mean+SD. P, 0.05 was considered to be statistically significant.
Ethics
The study protocols and informed consent forms were approved by the Institutional Review Board of the Asian Clinical Research Group (part of CREC Net, Kitakyushu, Japan) ethics committee before study initiation. The patients provided written consent to study participation, which was conducted in accordance with the Declaration of Helsinki. The study was registered with UMIN Clinical Trials Registry (UMIN-CTR), Japan (UMINI000004307) and has been completed.
Results
Study population
In total, 200 participants were registered between May 2010 and May 2011 from 35 study institutes across Japan. Of the participants, 97 were randomized into the 3 day treatment group and 103 into the 7 day treatment group. The median age was 49.5 years (range 20-80 years) for the 3 day group and 47 years (range 21-81 years) for the 7 day group. The allocation and flow of participants for analysis are shown in Figure 1 . In total, 161 bacterial strains were isolated from urine samples of 154 participants (Table 1) . Gram-negative bacteria accounted for 83.2% (134/161) of the bacteria and the largest proportion was E. coli (73.9%, 119/161).
Evaluations 5-9 days after treatment completion (Table 2) By intention-to-treat (ITT) analysis, microbiological efficacy of the 3 day treatment group was 58.9% eradication (43/73), 20.5% persistence (15/73) and 8.2% replaced (6/73) classifications, whereas the 7 day treatment resulted in 66.7% eradication (54/ 81), 6.2% persistence (5/81) and 7.4% replaced (6/81) classifications (P ¼ 0.048). The clinical efficacy rates were 76.7% (56/73) in the 3 day treatment group and 80.2% (65/81) in the 7 day treatment group (P ¼ 0.695).
Evaluations 4-6 weeks after treatment completion (Table 2) According to the results obtained 5-9 days after treatment completion, 32 participants with treatment failure were excluded from the ITT analysis at 4 -6 weeks after treatment completion. The microbiological efficacy rate in the 3 day treatment group was 40.4% (21/52), whereas in the 7 day treatment group it was 38.5% (27/70, P ¼ 0.839). The clinical efficacy rate in the 3 day treatment group was 46.2% (24/52), whereas in the 7 day treatment group it was 50.0% (35/70, P ¼ 0.717). When the nonrecurrence rate was evaluated by per-protocol (PP) analysis by Faropenem for uncomplicated cystitis: RCT additional exclusion of participants who dropped out of follow-up or were not assessed for microbiological outcome, the microbiological non-recurrence rate was 80.8% (21/26) in the 3 day treatment group and 79.4% (27/34) in the 7 day treatment group (P ¼ 1.000).
Safety (adverse events)
Safety was evaluated for all 200 registered participants. Adverse events were reported in 9.5% of participants (19/200) (Table 3) and there was no significant difference between the 3 and 7 day treatment groups. The most common adverse event was diarrhoea (7.5%, 15/200). Adverse event severity was mild to moderate.
Antimicrobial susceptibilities of isolates
In total, 161 causative pathogen strains were isolated, and antimicrobial susceptibility was examined for faropenem, cefcapene, fosfomycin and levofloxacin. MIC 50 and MIC 90 values for the organisms and their ranges are given in Table 4 . The MIC distribution for E. coli is shown in Table 5 . Some strains had high MICs of levofloxacin, cefcapene or fosfomycin. According to CLSI recommendations, 15 9.2% strains (11/119) were fluoroquinolone resistant and 3.4% (4/119) were ESBL-producing strains (CTX-M-14). The highest faropenem MIC was 2 mg/L, and this strain was eradicated after 7 days of treatment.
Discussion
A number of trials for acute uncomplicated cystitis showed that shorter treatment regimens of fosfomycin trometamol, pivmecillinam, fluoroquinolones or trimethoprim/sulfamethoxazole had the advantages of fewer adverse events, lower costs and better patient compliance. 16 -19 Among b-lactams, only a 3 day regimen with cefpodoxime proxetil showed equivalent efficacy to a 3 day regimen with trimethoprim/sulfamethoxazole. 20 Before our trial, we assumed that a 3 day regimen with faropenem could achieve 12,21 -23 The spread of antimicrobial-resistant bacteria has become a large problem around the world, and pathogens of acute uncomplicated cystitis are no exception. 1 -3,16,17,24 The activity of faropenem against ESBL-producing Enterobacteriaceae was believed to be greater than that of oral penicillins with b-lactamase inhibitors, but weaker than that of carbapenems, and faropenem has the greatest activity against ESBL-producing Gram-negative bacilli among oral antimicrobials. 14, 22 In our study, four ESBL-producing E. coli strains were detected and three were eradicated by faropenem treatment. These ESBL-producing strains had CTX-M14, which is now the most common ESBL in Japan. In addition, three of four ESBL-producing E. coli strains were resistant to fluoroquinolones and were eradicated by faropenem. Among 11 fluoroquinolone-resistant E. coli strains, 7 were eradicated in this study.
Cystitis patients are usually treated in the outpatient department. When fluoroquinolones or oral cephalosporins fail, different therapies are used. Recent Japanese surveillance of antimicrobial susceptibilities of pathogens from cystitis patients demonstrated that 30% of fluoroquinolone-resistant E. coli strains produced ESBLs, and 70% of ESBL-producing E. coli were fluoroquinolone-resistant. 24 These data suggest that switch therapy, especially switching from oral cephalosporins to fluoroquinolones, would not be advisable. When ESBL-producing strains were detected in cystitis patients, we used parenteral antimicrobials such as penicillins with b-lactamase inhibitors or carbapenems in the outpatient department. For these cases, faropenem could be a therapy option. Our study is the first to suggest that faropenem can be used for cystitis, and we believe that this study is applicable to Eastern Asia, Turkey and other regions. Clinical trials of pivmecillinam for ESBL-producing Gram-negative bacilli in UTIs were reported recently, and showed some clinical and microbiological efficacy. 25, 26 A study comparing faropenem with pivmecillinam for the treatment of cystitis should be planned.
Conclusions
The clinical and microbiological efficacy of faropenem sodium for cystitis was evaluated in this multicentre, randomized, openlabel, controlled study. The optimal regimen of faropenem for cystitis was determined to be 200 mg three times daily for 7 days. The most commonly observed adverse effect was diarrhoea, which was already known, and no other unknown adverse effects were reported. E. coli strains resistant to fluoroquinolones or cephalosporins showed high susceptibility to faropenem. We believe that faropenem is an oral penem antimicrobial with firstline drug potency for cystitis treatment. Faropenem for uncomplicated cystitis: RCT
